• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Alpha Cognition Inc.

    Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Appointment of VP Finance and Accounting
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Change of Officer
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOG CSE:ACOG
    Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Provides Business Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Launches $6.5 Million Private Placement
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF CSE:ACOG
    Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX:ACOG
    Alpha Cognition Provides Private Placement Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Grant of Stock Options
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces First Quarter 2022 Results and Company Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
    From Alpha Cognition Inc.
    Via Business Wire
    Tickers ACOGF TSX-V:ACOG
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.